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Background: Plasma triglyceride (TG) levels are known to confer an increased risk of vascular disease in
healthy populations, but data in high-risk patients are scarce. In this study we evaluated the risk on recurrent
vascular events conferred by increased plasma TG levels in patients with various clinical manifestations of
vascular disease.
Methods: Prospective cohort study of 5731 patients with clinically manifest vascular disease.
Results: First new vascular events (myocardial infarction, ischemic stroke, vascular death) occurred in 782
subjects during a median follow-up of 4.9 years (interquartile range 2.5–8.1 years). Patients in the highest
plasma TG quintile (>2.24 mmol/L) had a higher risk for recurrent vascular events (HR 1.45; 95%CI
1.13–1.86) compared with the lowest plasma TG quintile (b0.97 mmol/L) after adjustments for age, gender,
body mass index, smoking, lipid-lowering medication and low-density lipoprotein-cholesterol. The increased
risk associated with increasing plasma TG levels was irrespective of the presence of type 2 diabetes (T2DM),
but only present in patients without the metabolic syndrome. Furthermore, the increased risk was particular-
ly present in patients with coronary artery disease (CAD) (HR 1.45; 95%CI 1.02–2.08) and was not modiﬁed
by other lipid levels (p-value for interaction >0.05). Plasma TG still contributed to vascular risk when other
lipid levels were at target level.
Conclusions: Higher plasma TG levels are associated with increased risk for recurrent vascular events, in par-
ticular in CAD patients. This increased risk is independent of the presence of T2DM and the use of lipid-
lowering medication and is not modiﬁed by other lipid levels.© 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Patients with clinical manifestations of vascular diseases are at high
risk for new vascular events, and due to improved medical treatment
and an aging population, their number is increasing. Although these pa-
tients are treated intensively for cardiovascular risk factors, they are still
at considerable risk for a recurrent vascular event. Due to an increasing
prevalence of obesity and obesity-related insulin resistance, the number
of individuals with hypertriglyceridemia is rising [1,2]. Elevated plasma
triglyceride (TG) levels lead to an atherogenic lipoprotein phenotype
consisting of high plasma TG levels, low high-density lipoprotein cho-
lesterol (HDL-C) levels and small dense low-density lipoprotein (LDL)Medicine, University Medical
The Netherlands. Tel.: +31
isseren).
nder the Elsevier OA license. particles [3]. Therefore, hypertriglyceridemia could contribute to the re-
sidual risk and it would be important to assess the risk associated with
plasma TG levels on recurrent vascular events in these high-risk pa-
tients against a background of well treated risk factors, including wide-
spread use of statin therapy.
Plasma TG level has been shown to be an independent risk factor
for vascular events in healthy populations [4,5] and in trials with pa-
tients with coronary artery disease [6,7]. However, drugs lowering
plasma TG levels have not clearly proven to be effective in preventing
vascular events [8,9]. Therefore TG levels are not deﬁned as a
treatment target in current guidelines, although a TG level of
b1.7 mmol/L is propagated as desirable [10,11]. Instead, non-high
density lipoprotein-cholesterol (nonHDL-C) is advocated as a treat-
ment target in patients with hypertriglyceridemia, as nonHDL-C, con-
trary to LDL-C, also includes TG-rich VLDL-particles [10,11]. However,
it is unclear whether plasma TG levels by itself still add to the risk
associated with higher nonHDL-C levels.
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lar events in patients with different manifestations of arterial vascular
diseasewas determined. Furthermore, itwas evaluatedwhether this as-
sociation was present irrespective of the presence of type 2 diabetes
(T2DM) or the metabolic syndrome, the use of lipid-lowering medica-
tion, and the location of vascular disease. Finally, modiﬁcation of the ef-
fect of plasma TG levels on vascular events by the level of several other




For the present study, data were used from the Second Manifestations of ARTerial
disease (SMART) cohort. This is a prospective, ongoing cohort study, designed to estab-
lish the presence of concomitant arterial diseases and risk factors for atherosclerosis in
patients with known arterial disease or a cardiovascular risk factor, who were newly
referred to the University Medical Center Utrecht. All patients gave written informed
consent, and the Medical Ethics Committee of the University Medical Center Utrecht
approved the study. After informed consent, patients underwent a vascular screening
protocol including a health questionnaire, laboratory measurements and physical ex-
amination. A detailed description of this study has been published previously [12].
For the present study, we used data of 5746 patients, enrolled in the SMART study
between September 1996 and March 2010, with either a history or recent diagnosis of
clinically manifest arterial disease: coronary artery disease (CAD) (n=3448), cerebro-
vascular disease (n=1612), peripheral artery disease and/or aneurysm of the abdom-
inal aorta(AAA) (n=1603). Patients could be classiﬁed into more than 1 disease
category. Patients with plasma TG ≥10 mmol/L (n=15) were excluded since this
most likely results from a rare genetic cause. Hence the study population consisted
of 5731 patients.
Single imputation methods were used to reduce missing covariate data for smok-
ing (n=23; 0.4%), body mass index (BMI) (n=8; 0.1%), TC (n=3; 0.1%) and HDL-C
(n=9; 0.2%), since complete case analysis leads to loss of statistical power and to bias.
2.2. Laboratory assessment
Baseline lipid levelswere obtained from fasting patients. Plasma TC and TGweremea-
sured using commercial enzymatic dry chemistry kits (Johnson and Johnson). HDL-C in
plasma was determined using a commercial enzymatic kit (Boehringer-Mannheim)
after precipitation of LDL-C and VLDL-C with sodium phosphotungstate magnesium chlo-
ride. LDL-C was calculated using the Friedewald formula up to a plasma TG level of
9 mmol/L, which is in line with data showing that the Friedewald formula can be used
up to this level [13]. Calculated LDL-C levels b0.5 mmol/L were regarded as unreliable
and not used for analyses. As a result, LDL-C levels could be calculated for 5718 of 5731pa-
tients (99.8%).
2.3. Follow-up
During follow-up, all study participants received a questionnaire every 6 months
to obtain information about hospitalizations and outpatient clinic visits. If the partici-
pants reported a possible event, all available relevant data were collected. Death of a
participant was reported by relatives, the general practitioner or the specialist who
treated the participant. All events were classiﬁed independently by three members of
the SMART Study Endpoint Committee, comprising physicians from different depart-
ments. Outcomes of interest for this study were vascular death, myocardial infarction
or ischemic stroke, and the composite of these vascular events. Follow-up duration
was deﬁned as the period between study inclusion and ﬁrst cardiovascular event or
death from any cause, date of loss to follow-up or the preselected date of 1 March 2010.
2.4. Data analysis
Cox proportional hazard models were used to calculate hazard ratios (HR) and cor-
responding 95% conﬁdence intervals (CI) for the occurrence of vascular events associ-
ated with plasma TG levels. If a patient had multiple events, the ﬁrst recorded event
was used in the analyses. Patients were censored if they were lost to follow-up. Plasma
TG levels were divided into quintiles, the lowest quintile served as reference. Three
models were built, model I with adjustment for age and gender and model II with ad-
ditional adjustments for BMI, use of lipid-lowering medication, LDL-C and smoking, all
potential confounders in the relationship between plasma TG and vascular events. In
order to study the effect of plasma TG on recurrent vascular events independent of
plasma HDL-C, additional adjustment for HDL-C was made in model III.
Subgroup analyses were performed stratiﬁed for the presence of T2DM and the
metabolic syndrome (as deﬁned according to the NCEP criteria [10]) and in patients
with CAD, CVD and PAD/AAA separately. Because some patients fell into more than
one vascular disease-manifestation category, adjustments were made for the presence
of other vascular diseases in each category. For the same reason, effect modiﬁcation by
vascular disease-manifestation category could not be statistically tested. Furthermore,subgroup analyses were performed in strata of low versus high levels of several lipo-
proteins (LDL-C, nonHDL-C, TC/HDL-C ratio and HDL-C), to assess whether the effect
of TG was still present when these lipoprotein levels are optimal according to current
guidelines. For LDL-C, a cut-off of b2.5 mmol/L (97 mg/dL) was deﬁned as optimal and
for nonHDL-C, a cut-off of b3.3 mmol/L was deﬁned as optimal, according to European
guidelines [11]. For HDL-C the NCEP ATP III cut-offs for metabolic syndrome were used:
>1.03 mmol/L (40 mg/dL) in men and >1.29 mmol/L (50 mg/dL) in women [10]. An
optimal TC/HDL-C ratio was deﬁned as b5. For these analyses, TG was log transformed
to have a normal distribution and used as a continuous variable.
In order to test for interaction, i.e. whether the relation between plasma TG levels
and vascular events was modiﬁed by LDL-C, nonHDL-C, HDL-C or TC/HDL category, we
included these interaction terms in the Cox model. If the p-value of the interaction
term was b0.05, effect-modiﬁcation was considered present.
Analyses were performed using the statistical package Predictive Analytics Soft-
Ware (PASW) Statistics 18.0. For all analyses, Pb0.05 was considered signiﬁcant.3. Results
3.1. Baseline characteristics
Baseline characteristics of the study population according to quin-
tiles of plasma TG are presented in Table 1. The prevalence of the met-
abolic syndrome increases from 14% in quintile 1 to 80% in quintile 5.
With increasing quintiles of plasma TG, the proportion of current
smokers increased, paralleled by an increase in the incidence of pe-
ripheral artery disease.3.2. Plasma TG levels and risk of new vascular events
During a median follow-up of 4.9 years (interquartile range
2.5–8.1 years), 782 ﬁrst new vascular events occurred. Overall, 193
(non-)fatal ischemic strokes, 451 (non-)fatal myocardial infarctions
and 473 vascular deaths occurred.
As shown in Table 2, the risk of vascular events increased across
quintiles of plasma TG and was 45% higher in the highest quintile
(HR 1.45; 95%CI 1.13–1.86) compared to the lowest quintile (model
2) for the combined endpoint. P for trend across quintiles was
0.002. The risk for ischemic stroke was 47% higher in the highest TG
quintile (HR 1.47; 95%CI 0.89–2.42) compared to the lowest TG quin-
tile, the risk for myocardial infarction 56% higher (HR 1.56; 95%CI
1.11–2.18) and the risk for vascular death 48% higher (HR 1.48;
95%CI 1.07–2.05). Additional adjustment for HDL-C (model 3), con-
siderably weakened the effect of plasma TG on all vascular endpoints
(HR for all vascular events: 1.22; 95%CI 0.93–1.60, highest quintile
compared to lowest quintile). Additional adjustment for nonHDL-C
instead of LDL-C in model 2 only slightly attenuated the effect of plas-
ma TG on vascular events (data not shown).
In patients without T2DM (n=4774), plasma TG in the highest
quintile increased the risk (HR 1.47; 95%CI 1.11–1.96) for all vascular
events compared plasma TG in the lowest quintile. In patients with
T2DM (n=957), the risk for all vascular events was only slightly
higher in quintile 5 compared to quintile 1 (HR 1.11; 95%CI
0.65–1.91), and the association between plasma TG and vascular
events seemed slightly u-shaped. When analyzed continuously, the
HR for all vascular events was similar for both groups (HR1.17;
95%CI 0.86–1.58 in T2DM vs. HR 1.23; 95%CI 1.04–1.46) and p for in-
teraction was 0.894. Plasma TG did increase the risk for all vascular
events in patients without the metabolic syndrome (HR 1.29; 95%CI
1.00–1.66, p=0.047 for log-TG), but not in patients with the meta-
bolic syndrome (HR 0.94; 95%CI 0.74–1.18, p=0.584 for log-TG); p
for interaction by the metabolic syndrome was 0.051. HOMA-IR was
only available in patients included from 2003 onwards and only few
events occurred in this group. However, when additional adjustment
was made for HOMA-IR in the non-diabetic patients, the hazard ratio
for TG (log-transformed) was 1.28 (0.88–1.87). Although this result
was not signiﬁcant due to the small group size, the risk estimate is
similar to the risk estimate in the entire group.
Table 1
Baseline characteristics of the study population according to quintiles of plasma triglycerides (TG).
Total population (n=5731) Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
Range TG (mmol/L) b0.97 0.97–1.24 1.25–1.60 1.61–2.24 >2.24
Median TG (mmol/L) 0.80 1.10 1.41 1.88 2.90
N 1163 1133 1158 1131 1146
Age (years) 60.5±11.1 60.8±10.2 61.0±10.3 59.5±10.3 58.3±9.8
Male gender, n (%) 843 (73) 820 (72) 855 (74) 813 (72) 914 (80)
BMI (kg/m2) 25.6±3.7 26.1±3.6 26.9±4.0 27.6±4.0 28.0±4.1
Waist circumference (cm) 91±12 93±11 96±12 98±11 100±11
Systolic blood pressure (mm Hg) 141±21 140±2 142±20 140±20 143±20
Diastolic blood pressure (mm Hg) 79±10 79±10 80±10 79±10 81±10
Total cholesterol (mmol/L) 4.3±1.0 4.7±1.1 4.9±1.1 5.2±1.1 5.6±1.2
HDL-C (mmol/L) 1.4±0.4 1.3±0.4 1.2±0.3 1.1±0.3 1.0±0.3
LDL-C (mmol/L) 2.5±0.9 2.8±1.0 3.1±1.0 3.2±1.0 3.1±1.2a
NonHDL-C (mmol/L) 2.9±0.9 3.3±1.0 3.7±1.0 4.0±1.0 4.6±1.2
Creatinine (μmol/L) 89±25 92±42 95±39 95±34 100±55
MDRD-GFR (mL/min/1.73 m2) 78±17 77±17 74±17 75±18 75±20
Type 2 diabetes mellitus, n (%) 147 (13) 148 (13) 174 (15) 207 (18) 281 (25)
Homa-IRb 2.1±1.4 2.6±2.0 3.0±2.0 3.3±2.3 4.0±3.1
Metabolic syndrome NCEP ATP III, n (%) 165 (14) 214 (19) 319 (28) 741 (66) 912 (80)
Current smoking, n (%) 312 (27) 328 (29) 387 (33) 399 (35) 475 (41)
Use of alcohol in the last year, n (%) 882 (76) 813 (72) 805 (70) 762 (67) 790 (69)
Antiplatelet/anticoagulant agents, n (%) 986 (85) 929 (82) 953 (82) 916 (81) 890 (78)
Use of blood pressure lowering agents, n (%) 804 (69) 833 (73) 846 (73) 858 (76) 858 (75)
Use of lipid-lowering agents, n (%) 811 (70) 755 (67) 707 (61) 711 (63) 657 (57)
Localization of vascular diseasec
Coronary arteries, n (%) 681 (59) 691 (61) 699 (60) 688 (61) 689 (60)
Cerebrovascular, n (%) 390 (34) 315 (28) 331 (29) 283 (25) 305 (27)
Aneurysm abdominal aorta, n (%) 77 (7) 98 (9) 107 (9) 112 (10) 119 (10)
Peripheral arteries, n (%) 164 (14) 208 (18) 233 (20) 264 (23) 312 (27)
Continuous variables are shown as mean±standard deviation.
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; LDL-C, low-density lipoprotein-
cholesterol; and MDRD-GFR, modiﬁcation of diet in renal disease-glomerular ﬁltration rate.
a Calculated with Friedewald formula up to plasma TG 9 mmol/L.
b Only measured from July 2003 onwards.
c Patients could be classiﬁed in more than 1 vascular disease category.
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localization of vascular disease
In patients with coronary artery disease, increasing levels of TG
were most clearly associated with increased risk of new vascular
events (Table 3). Compared to quintile 1, the risk of new vascular
events was increased with 45% in quintile 5 (HR 1.45; 95%CI
1.02–2.08). P for trend across quintiles was 0.027. After adjustmentTable 2
Risk of new vascular events in quintiles of plasma TG.
Model Quintile 1 Quintile 2
TG range (mmol/L) b0.97 0.97–1.24
N=5731 1163 1133
Ischemic stroke # events 24 29
I Reference 1.04 (0.60
II Reference 0.96 (0.56
Myocardial infarction # events 52 75
I Reference 1.22 (0.85
II Reference 1.18 (0.83
Vascular death # events 55 80
I Reference 1.18 (0.84
II Reference 1.13 (0.80
All vascular events # events 96 134
I Reference 1.17 (0.90
II Reference 1.11 (0.86
Hazard ratio (95% conﬁdence interval), adjusted for:
Model I: age and gender.
Model II: Model I+smoking, lipid-lowering medication, BMI and LDL-C.
Abbreviations: as in Table 1.
⁎ pb0.05.
⁎⁎ pb0.01.for HDL-C (model 3), higher TG levels the increase in risk did not
reach statistical signiﬁcance anymore (HR 1.34; 95%CI 0.92–1.96). In
patients with cerebrovascular disease the risk in quintile 5 was
slightly increased compared to quintile 1, although this was not sta-
tistically signiﬁcant. Moreover, there was no clear trend across quin-
tiles (p for trend 0.315). In peripheral artery disease/AAA there was
no relation between TG plasma levels and risk of future vascular
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–1.65) 1.06 (0.63–1.79) 1.23 (0.74–2.06) 1.47 (0.89–2.42)
99 100 125
–1.73) 1.39 (0.99–1.94) 1.43 (1.02–2.00)⁎ 1.67 (1.20–2.31)⁎⁎
–1.68) 1.31 (0.93–1.84) 1.36 (0.96–1.92) 1.56 (1.11–2.18)⁎
112 98 128
–1.67) 1.35 (0.97–1.86) 1.27 (0.91–1.77) 1.62 (1.18–1.77)⁎⁎
–1.59) 1.24 (0.89–1.72) 1.19 (0.85–1.67) 1.48 (1.07–2.05)⁎
170 169 213
–1.52) 1.29 (1.00–1.65) 1.32 (1.02–1.69)⁎ 1.59 (1.25–2.03)⁎⁎
–1.45) 1.18 (0.91–1.52) 1.22 (0.94–1.58) 1.45 (1.13–1.86)⁎
Table 3
Risk of new vascular events in quintiles of plasma TG according to localization of vascular disease.
TG range (mmol/L) Model Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
b0.97 0.97–1.24 1.25–1.60 1.61–2.24 >2.24
Patients with coronary artery disease (n=3448) # events/N 45/681 71/691 89/699 98/688 122/689
I Reference 1.30 (0.89–1.88) 1.36 (0.94–1.95) 1.55 (1.08–2.20)⁎ 1.61 (1.14–2.28)⁎⁎
II Reference 1.22 (0.84–1.78) 1.24 (0.86–1.79) 1.43 (0.99–2.05) 1.45 (1.02–2.08)⁎
Patients with cerebrovascular disease (n=1624) # events/N 34/390 41/315 71/331 60/283 70/305
I Reference 1.19 (0.76–1.88) 1.47 (0.98–2.23) 1.45 (0.95–2.22) 1.38 (0.91–2.10)
II Reference 1.10 (0.70–1.76) 1.30 (0.85–1.99) 1.27 (0.81–1.97) 1.25 (0.81–1.92)
Patients with peripheral artery disease/AAA (n=1603) # events/N 39/235 62/286 78/323 74/353 110/406
I Reference 0.96 (0.64–1.44) 1.02 (0.70–1.43) 0.97 (0.66–1.43) 1.13 (0.78–1.64)
II Reference 0.95 (0.63–1.42) 1.00 (0.68–1.47) 0.99 (0.66–1.47) 1.15 (0.79–1.69)
Hazard ratio (95% conﬁdence interval), adjusted for:
Model I: age and gender+vascular disease at other localization.
Model II: Model I+smoking, lipid-lowering medication, BMI and LDL-C.
Vascular events: composite of myocardial infarction, ischemic stroke and vascular death.
Patients could be classiﬁed in more than 1 vascular disease category.
Abbreviations: AAA, aneurysm of the abdominal aorta. Further as in Table 1.
⁎ pb0.05.
⁎⁎ pb0.01.
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levels of LDL-C, nonHDL-C, HDL-C and TC/HDL-C ratio
As displayed in Table 4, higher plasma log-TG levels were still as-
sociated with increased risk of new vascular events when other lipids
are at target level. Although the increase in risk with increasing plas-
ma log-TG was statistically signiﬁcant in some strata and not in
others, the overall effect was not modiﬁed by either high or low stra-
tum.When stratiﬁed for LDL-C, nonHDL-C, HDL-C and TC/HDL-C ratio,
p for interaction was 0.472, 0.247, 0.774 and 0.151 respectively,
which implies that the risk conferred by TG is not different regardless
of other lipid levels.
Fig. 1 visualizes the risk of vascular events across plasma TG quin-
tiles according to strata for LDL-C, nonHDL-C, HDL-C and TC/HDL-C
ratio at baseline. The lower risk lipid stratum in the low TG quintile
served as a reference category. This ﬁgure illustrates the results pre-
sented in Table 4, showing an increased risk with increasing plasma
TG-levels irrespective of other lipid levels, and showing a contribu-
tion of plasma TG levels to increased vascular risk even when other
lipids are at target level.Table 4
Risk of new vascular events conferred by plasma log-triglyceride levels, stratiﬁed for
other lipoprotein levels at baseline.
LDL-C b2.5 mmol/L ≥2.5 mmol/L
Events/N 169/2118 613/3613
HR Model I 1.30 (1.00–1.69)⁎ 1.31 (1.10–1.55)⁎⁎
HR Model II 1.27 (0.97–1.67) 1.29 (1.08–1.53)⁎⁎
NonHDL-C b3.3 mmol/L ≥3.3 mmol/L
Events/N 178/2319 604/3412
HR Model I 1.21 (0.86–1.70) 1.22 (1.03–1.44)⁎
HR Model II 1.25 (0.88–1.78) 1.22 (1.03–1.45)⁎
HDL-C b1.03 (M); 1.29 (F) mmol/L ≥1.03 (M); 1.29 (F) mmol/L
Events/N 360/2279 422/3452
HR Model I 1.16 (0.94–1.44) 1.34 (1.08–1.65)⁎⁎
HR Model II 1.14 (0.91–1.43) 1.22 (0.97–1.52)
TC/HDL-C ratio b5 ≥5
Events/N 445/4098 337/1633
HR Model I 1.20 (0.97–1.50) 1.15 (0.91–1.44)
HR Model II 1.20 (0.96–1.51) 1.18 (0.93–1.49)
Hazard ratio (95% conﬁdence interval), adjusted for:
Model I: age and gender.
Model II: Model I+smoking, lipid-lowering medication, BMI and LDL-C (adjustment
for LDL-C only when stratiﬁed for HDL-C).
Abbreviations: TC, total cholesterol. Further as in Table 1.
⁎ pb0.05.
⁎⁎ pb0.01.4. Discussion
In patients with clinicallymanifest vascular diseases, high plasma TG
levels increase the risk of recurrent vascular events, particularly in pa-
tients with CAD. This risk is independent of the presence of T2DM and
the use of lipid-lowering medication. Higher plasma TG levels increase
risk in patients with either low (b2.5 mmol/L) or high (≥2.5 mmol/L)
LDL-C and either low (b3.3 mmol/L) or high (≥3.3 mmol/L) nonHDL-C
levels.
Previous meta-analyses showed that plasma TG is a risk factor for
the development of cardiovascular diseases in healthy populations,
independent of HDL-C [4,5]. In patients with known CAD who were
treated with statins, plasma TG levels have been shown a risk factor
for recurrent vascular events, even at low LDL-C levels [7,6]. The pre-
sent study expands the results of previous trials to an unselected pop-
ulation of patients with CADwho are encountered in everyday clinical
practice and treated intensively with lipid-lowering medication.
However, plasma TG levels were not associated with an increased
risk for recurrent vascular events in patients with CVD, PAD or AAA.
Since the different vascular disease categories were not mutually ex-
clusive, presence of interaction by location of vascular disease could
not be statistically tested. The difference in vascular risk by plasma
TG between these disease categories may be partially explained by
the different metabolic proﬁle of patients with CAD compared to pa-
tients with vascular disease at other locations. In our study, patients
with coronary artery disease had a higher average BMI and waist cir-
cumference, but they had a lower blood pressure and were less likely
to smoke. Therefore, vascular events in these patients may result from
adipose tissue dysfunction and increase in plasma TG and may be ‘fat-
driven’, more than in patients with vascular diseases at different loca-
tions. In short, these results show that in the current era of intensive
treatment of vascular risk factors, plasma TG levels still contribute to
residual risk, in particular in patients with CAD.
Higher plasma TG levels may be seen as a marker of insulin resis-
tance, as is present in obesity, metabolic syndrome and T2DM, condi-
tions known to be associated with an increased cardiovascular risk
[14]. Still, our results show that the risk associated with plasma TG is
not due to its association with BMI, the metabolic syndrome or T2DM.
Adjustment for BMI or stratiﬁcation for T2DM did not essentially affect
the vascular risk associatedwith high plasma TG, indicating that plasma
TG is an independent risk factor for vascular events in patients with
clinically manifest vascular disease. Also adjustment for HOMA-IR did
not change the risk associatedwith plasma TG, making subclinical insu-
lin resistance as an explanation unlikely. Only in patients with the met-
abolic syndrome, the risk associatedwith plasmaTG seems to be absent.
Fig. 1. Risk for new vascular events for quintiles of TG stratiﬁed for other lipoprotein measures at baseline.All HRs were adjusted for age, gender, smoking, lipid-lowering medication
and BMI. In Fig. 1c, additional adjustment was made for LDL-C. * pb0.05; ** pb0.01.
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tribute risk in this metabolically unhealthy state; or that patients with
metabolic syndrome but still low plasma TG levels have other comor-
bidities that decrease plasma TG.
Also after adjustment for LDL-C or nonHDL-C, high plasma TG
levels were associated with higher risk of recurrent vascular events,
in accordance with other studies in healthy populations and statin tri-
als [7,15]. Thus, these results may suggest a beneﬁcial effect of lower-
ing plasma TG in secondary prevention. However, drugs lowering
plasma TG levels, such as ﬁbrates, have not clearly proven to be effec-
tive in preventing vascular events [8,9]. Therefore, triglyceride levels
are not used as treatment targets in current guidelines [10,11]. In-
stead, NCEP ATP III guidelines advise nonHDL-C as the treatment tar-
get in patients with TG >2.3 mmol/L (200 mg/dL). NonHDL-C
includes TG-rich VLDL-particles in contrast to LDL-C [10]. Data from
the present study show that the risk associated with high TG levels
is independent of nonHDL-C. Fig. 1 shows an increased risk with TG
even when the nonHDL-C target has been reached, although this in-
creased risk pertains only to the highest TG quintile, which is a
small group of the patients with nonHDL b3.3 mmol/L and therefore
the conﬁdence intervals are large and include 1. However, this may
still imply that current lipid targets do not sufﬁce in all patients
with high TG and a search for other approaches to reduce plasma
TG-associated residual risk may be worthwhile.
Apolipoprotein B (apoB) levels may explain the risk associated
with plasma TG when nonHDL-C levels are low and have been pro-
posed to estimate risk in hypertriglyceridemic patients. The Mercury
II trial showed that for patients with TG ≥2.3 mmol/L (≥200 mg/dL)
only 37% of the patients reaching the nonHDL-C goal of 3.37 mmol/L
(130 mg/dL) during statin therapy also reached the apoB goal of
90 mg/dL [16]. In the present study apoB was only available for
2075 patients, and consequently we could not verify this explanation.
The Mercury II study also showed that on statin therapy a stricter
nonHDL-C target (b2.6 mmol/L) is necessary to attain this apoB target
[16]. More studies are necessary to establish whether TG still confers
additional risk at these low apoB/nonHDL-C goals.
In the present study, the risk associated with higher plasma TG
levels disappeared after adjustment for HDL-C, which is tightly cor-
related with plasma TG. TG from TG-rich particles are transferred to
HDL particles in exchange for cholesterol via cholesteryl ester trans-
ferase protein (CETP), after which the TG-enriched HDL particles arerapidly cleared [17]. As HDL-C concentrations are more stable than
TG concentrations, the relation of HDL-C with vascular events may
be clearer. However, a part of the risk associated with low HDL-C
may actually reﬂect risk associated with increased levels of VLDL
remnants and small dense LDL. The present results show a trend to-
wards an increased risk associated with higher TG levels even if
HDL-C is high.
A clinical implication of these results is the need for increased atten-
tion for plasma TG levels, in particular in patients with CAD. To reduce
residual risk, lowering plasma LDL-C or even nonHDL-C to current tar-
gets may not be sufﬁcient. As long as there are no TG-lowering drugs
proven to be effective in reducing vascular events, focus should be on
a strict nonHDL-C target. In patients with elevated plasma TG levels
(≥2.3 mmol/L=≥200 mg/dL or even 1.7 mmol/L=≥150 mg/dL) a
strict nonHDL-C target (2.6 mmol/L=100 mg/dL) could be deﬁned to
lower the risk associated with plasma TG.
We acknowledge several limitations of the study. First, apoB levels
were only available for a small proportion of patients, disabling the
use in additional analyses. Furthermore, only baseline lipid levels
were available. The use of lipid-lowering medication at baseline was
64%. It is likely that during follow-up lipid-lowering therapy was
started in more patients, inﬂuencing plasma lipid levels. However,
this will probably have resulted in only small changes in plasma TG
levels. Moreover, the effect of starting lipid-lowering therapy will
most likely result in a small underestimation of the effect of plasma
TG, as the proportion of patients with lipid-lowering therapy at base-
line was lowest in patients with high plasma TG.
In conclusion, high plasma TG levels confer an increased risk for
recurrent vascular events in patients with clinically manifest vascular
disease, especially patients with CAD. This relationship was indepen-
dent of LDL-C and use of lipid-lowering medication and is present
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